5月25日，据CDE官网消息，劲方医药科技（上海）股份有限公司联合申请药品“GFH312 片”，获得临床试验默示许可，受理号CXHL2500273。
公示信息显示，药品“GFH312 片”适应症：拟用于原发性胆汁性胆管炎。
劲方医药科技（上海）股份有限公司，成立于2017年，位于上海市，是一家以从事研究和试验发展为主的企业。企业注册资本2677.4063万人民币，实缴资本2202.703398万人民币。
通过天眼查大数据分析，劲方医药科技（上海）股份有限公司共对外投资了5家企业，知识产权方面有商标信息5条，专利信息14条，此外企业还拥有行政许可19个。
主要股东信息显示，劲方医药科技（上海）股份有限公司由健发药业（香港）有限公司持股16.331%、Ourea Biotech HK Limited持股9.3583%、长星成长集团有限公司持股5.6365%、上海坤劲企业管理咨询合伙企业（有限合伙）持股5.1677%、鸿永秉德（香港）有限公司持股4.9196%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.